DS 8273

Drug Profile

DS 8273

Alternative Names: Anti-DR5 monoclonal antibody - Daiichi Sankyo; DS-8273a; DS8273

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Daiichi Sankyo Inc
  • Developer Bristol-Myers Squibb; Daiichi Sankyo Inc; New York University School of Medicine
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Immunomodulators; TRAIL receptor 2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Colorectal cancer; Malignant melanoma
  • No development reported Lymphoma; Solid tumours

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Lymphoma(Late-stage disease) in USA (IV)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in USA (IV)
  • 29 Sep 2017 Bristol-Myers Squibb terminates a phase I trial due to business decision in Colorectal cancer (Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater, Late-stage disease, Combination therapy) in USA (IV) (NCT02991196)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top